Systemic lupus erythematosus (SLE)–related arthritis has been traditionally defined as non-erosive and is therefore considered a minor manifestation requiring a mild treatment. However, the concept of non-erosive arthritis in SLE has been challenged with the advent of sensitive imaging techniques, such as high-resolution ultrasound with power Doppler or magnetic resonance. The application of these new imaging tools has demonstrated that up to 40% of SLE patients with joint involvement can develop erosive damage. Thus, this more aggressive phenotype can be identified not only in patients overlapping with rheumatoid arthritis (RA). This issue has been considered for the first time in the classification criteria proposed by Systemic Lupus International Collaborating Clinics in 2012, in which the old definition of “non-erosive arthritis” was replaced with either synovitis or tenderness in two or more joints with morning stiffness, suggesting the possible presence of an erosive phenotype. Accordingly, the 2019 EULAR/ACR’s SLE recommendations advise treatment with immunosuppressant or biological drugs for patients with RA-like moderate arthritis. As a result, several studies have investigated the presence of biomarkers associated with SLE erosive damage. A relevant role seems to be played by the autoantibodies directed against post-translational modified proteins: above all, a significant association has been observed with antibodies directed against citrullinated and carbamylated proteins. Conversely, the rheumatoid factor was not associated with this more aggressive SLE-related arthritis. Nonetheless, some pro-inflammatory factors have been associated with erosive damage in SLE patients. These results suggest new pathogenic mechanisms underlining erosive arthritis, only partially shared with RA. Hence, in the present narrative review, we summarized available data about erosive arthritis in SLE patients, in the light of its impact on therapeutic decisions.
CeccarelliFPerriconeCCiprianoE, et al.Joint involvement in systemic lupus erythematosus: from pathogenesis to clinical assessment. Semin Arthritis Rheum2017; 47: 53–64.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40(9): 1725.
4.
PetriMOrbaiAMAlarcónGS, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64(8): 2677–2686.
5.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2019; 71(9): 1400–1412.
6.
FanouriakisAKostopoulouMAlunnoA, et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78(6): 736–745.
7.
SipplNFaustiniFRönnelidJ, et al.Arthritis in systemic lupus erythematosus is characterized by local IL-17A and IL-6 expression in synovial fluid. Clin Exp Immunol2021; 205(1): 44–52.
8.
BoiniSGuilleminF. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis2001; 60: 817–827.
9.
WeissmanBNRappoportASSosmanJL, et al.Radiographic findings in the hands in patients with systemic lupus erythematosus. Radiology1978; 126: 313–317.
10.
LandewéRvan de HeijdeD. Is radiographic progression a realistic outcome measure in clinical trials with early inflammatory arthritis?Clin Exp Rheumatol2003; 21: S37–S41.
11.
AletahaDNeogiTSilmanAJ, et al.2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum2010; 62: 2569–2581.
12.
TangHQuXYueB. Diagnostic test accuracy of magnetic resonance imaging and ultrasound for detecting bone erosion in patients with rheumatoid arthritis. Clin Rheumatol2019; 39(4): 1283–1293.
13.
D'AgostinoMATerslevLAegerterP, et al.Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open2017; 3(1): e000428.
14.
FilippucciECipollettaEMashadiMirzaR, et al.Ultrasoundimaging in rheumatoidarthritis. Radiol Med2019; 124: 1087–1100.
15.
PerriconeCCeccarelliFModestiM, et al.The 6-joint ultrasonographic assessment: a valid, sensitive-to-change and feasible method for evaluating joint inflammation in RA. Rheumatology (Oxford)2012; 51: 866–873.
16.
SzkudlarekMTerslevLWakefieldRJ, et al.Summary findings of a systematic literature review of the ultrasound assessment of bone erosions in rheumatoid arthritis. J Rheumatol2016; 43: 12–21.
17.
DøhnUMEjbjergBJCourt-PayenM, et al.Are bone erosions detected by magnetic resonance imaging and ultrasonography true erosions? A comparison with computed tomography in rheumatoid arthritis metacarpophalangeal joints. Arthritis Res Ther2006; 8(4): R110
18.
WangMYWangXBSunXH, et al.Diagnostic value of high-frequency ultrasound and magnetic resonance imaging in early rheumatoid arthritis. Exp Ther Med2016; 12: 3035–3040.
19.
HumbyFMahtoAAhmedM, et al.The relationship between synovial pathobiology and magnetic resonance imaging abnormalities in rheumatoid arthritis: a systematic review. J Rheumatol2017; 44: 1311–1324.
20.
HaavardsholmEABøyesenPØstergaardM, et al.Magnetic resonance imaging findings in 84 patients with early rheumatoid arthritis: bone marrow oedema predicts erosive progression. Ann Rheum Dis2008; 67(6): 794–800.
21.
ChakravartyANawareSS. Cost-effectiveness analysis for technology acquisition. Med Journal, Armed Forces India2008; 64(2): 168.
22.
WongPCLeeGSedieAD, et al.Musculoskeletal ultrasound in systemic lupus erythematosus: systematic literature review by the lupus task force of the OMERACT ultrasound working group. J Rheumatol2019; 46: 1379–1387.
23.
IagnoccoAOssandonACoariG, et al.Wrist joint involvement in systemic lupus erythematosus. An ultrasonographic study. Clin Exp Rheumatol2004; 22: 621–624.
24.
WrightSFilippucciEGrassiW, et al.Hand arthritis in systemic lupus erythematosus: an ultrasound pictorial essay. Lupus2006; 15: 501–506.
25.
Delle SedieARienteLScirèCAet al.Ultrasound Imaging for the rheumatologist. XXIV. Sonographic evaluation of wrist and hand joint and tendon involvement in systemic lupus erythematosus. Clin Exp Rheumatol2009; 27: 897–901.
26.
DemirkayaEOzçakarLTürkerT, et al.Musculoskeletal sonography in juvenile systemic lupus erythematosus. Arthritis Rheum2009; 61: 58–60.
27.
OssandonAIagnoccoAAlessandriC, et al.Ultrasonographic depiction of knee joint alterations in systemic lupus erythematosus. Clin Exp Rheumatol2009; 27: 329–332.
28.
GabbaAPigaMVaccaA, et al.Joint and tendon involvement in systemic lupus erythematosus: an ultrasound study of hands and wrists in 108 patients. Rheumatology2012; 51(12): 2278–2285.
29.
BallEMGibsonDSBellAL, et al.Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus2014; 23: 46–56.
30.
DreyerLJacobsenSJuulL, et al.Ultrasonographic abnormalities and inter-reader reliability in Danish patients with systemic lupus erythematosus - a comparison with clinical examination of wrist and metacarpophalangeal joints. Lupus2015; 24: 712–719.
31.
MoscaMTaniCCarliL, et al.The role of imaging in the evaluation of joint involvement in 102 consecutive patients with systemic lupus erythematosus. Autoimmun Rev2015; 14: 10–15.
32.
PigaMSabaLGabbaA, et al.Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritis: comparison with computed tomography. Arthritis Res Ther2016; 18: 222.
33.
CeccarelliFPerriconeCColasantiT, et al.Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus. Arthritis Res Ther2018; 20: 126.
34.
ZayatASMahmoudKMd YusofMY, et al.Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology (Oxford)2019; 58: 304–312.
35.
Di MatteoADe AngelisRCipollettaE, et al.Systemic lupus erythematosus arthropathy: the sonographic perspective. Lupus2018; 27: 794–801.
36.
TangHLiuYZhaoH. Comparison of role of hand and wrist ultrasound in diagnosis of subclinical synovitis in patients with systemic lupus erythematosus and rheumatoid arthritis: a retrospective, single-center study. Med Sci Monit2020; 26: 926436.
37.
SalliotCDenisADernisE, et al.Ultrasonography and detection of subclinical joints and tendons involvements in Systemic Lupus erythematosus (SLE) patients: a cross-sectional multicenter study. Joint Bone Spine2018; 85: 741–745.
38.
OstendorfBSchererASpeckerC, et al.Jaccoud's arthropathy in systemic lupus erythematosus: differentiation of deforming and erosive patterns by magnetic resonance imaging. Arthritis Rheum2003; 48: 157–165.
39.
BoutryNHachullaEFlipoRM, et al.MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjögren syndrome. Radiology2005; 236: 593–600.
40.
SáRibeiroDGalvãoVLuiz FernandesJ, et al.Magnetic resonance imaging of Jaccoud's arthropathy in systemic lupus erythematosus. Joint Bone Spine. 2010; 77: 241–245.
41.
BallEMTanALFukubaE, et al.A study of erosive phenotypes in lupus arthritis using magnetic resonance imaging and anti-citrullinated protein antibody, anti-RA33 and RF autoantibody status. Rheumatology (Oxford)2014; 53: 1835–1843.
42.
SantiagoMBGalvãoVRibeiroDS, et al.Severe Jaccoud's arthropathy in systemic lupus erythematosus. Rheumatol Int2015; 35: 1773–1777.
43.
TaniCD'AnielloDPossematoN, et al.MRI pattern of arthritis in systemic lupus erythematosus: a comparative study with rheumatoid arthritis and healthy subjects. Skeletal Radiol2015; 44: 261–266.
44.
van VugtRMDerksenRHKaterL, et al.Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis1998; 57: 540–544.
45.
SaketkooLAQuinetR. Revisiting Jaccoud arthropathy as an ultrasound diagnosed erosive arthropathy in systemic lupus erythematosus. J Clin Rheumatol2007; 13: 322–327.
CeccarelliFMassaroLPerriconeC, et al.Jaccoud's arthropathy in systemic lupus erythematosus: clinical, laboratory and ultrasonographic features. Clin Exp Rheumatol. 2017; 35: 674–677.
48.
LinsCFde Sá RibeiroDLSantosWGD, et al.Sonographic findings of hands and wrists in systemic lupus erythematosus patients withjaccoud arthropathy. J Clin Rheumatol2018; 24: 70–74.
49.
MastrangeloAColasantiTBarbatiC, et al.The role of post translational proteinmodifications in rheumatologicaldiseases: focus on rheumatoidarthritis. J Immunol Res2015; 2015: 712490.
50.
AggarwalRLiaoKNairR, et al.Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum2009; 61: 1472–1483.
51.
Rantapaa-DahlqvistSde JongBABerglinE, et al.Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum2003; 48: 2741–2749.
52.
NielenMMvan SchaardenburgDReesinkHW, et al.Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum2004; 50: 380–386.
MediwakeRIsenbergDASchellekensGA, et al.Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis2001; 60: 67–68.
55.
Amezcua-GuerraLMSpringallRMarquez-VelascoR, et al.Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. Arthritis Res Ther2006; 8: R144.
56.
ChanMTOwenPDunphyJ, et al.Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J Rheumatol2008; 35: 77–83.
57.
Damián-AbregoGNCabiedesJCabralAR. Anti-citrullinated peptide antibodies in lupus patients with or without deforming arthropathy. Lupus2008; 17: 300–304.
58.
QingYFZhangQBZhouJG, et al.The detecting and clinical value of anti-cyclic citrullinated peptide antibodies in patients with systemic lupus erythematosus. Lupus2009; 18: 713–717.
59.
ZhaoYLiJLiXX, et al.What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus?Joint Bone Spine2009; 76: 501–507.
60.
KakumanuPSobelESNarainS, et al.Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis. J Rheumatol2009; 36: 2682–2690.
61.
TaraborelliMInverardiFFrediM, et al.Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease?Reumatismo2012; 64: 321–325.
62.
SkareTLNisiharaRBarbosaBB, et al.Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients. Clin Rheumatol2013; 32: 1065–1070.
63.
ZiegelaschMvan DelftMAWallinP, et al.Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. Arthritis Res Ther2016; 18: 289.
64.
BudhramAChuRRusta-SallehyS, et al.Anti-cyclic citrullinated peptide antibody as a marker of erosive arthritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Lupus2014; 23: 1156–1163.
65.
ShiJvan de StadtLALevarhtEW, et al.Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis2014; 73: 780–783.
66.
ShiJvan de StadtLALevarhtEW, et al.Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum2013; 65: 911–915.
67.
van DelftMAMVerheulMKBurgersLE, et al.The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. Arthritis Res Ther2017; 19: 190.
68.
TruchetetMEDublancSBarnetcheT, et al.Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: data from the French ESPOIR cohort. Arthritis Rheumatol2017; 69: 2292–2302.
69.
PecaniAAlessandriCSpinelliFR, et al.Prevalence, sensitivity and specificity of antibodies against carbamylated proteins in a monocentric cohort of patients with rheumatoid arthritis and other autoimmune rheumatic diseases. Arthritis Res Ther2016; 18: 276.
70.
MassaroLCeccarelliFColasantiT, et al.Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement. Lupus2018; 27(1): 105–111.
71.
CeccarelliFSciandroneMPerriconeC, et al.Biomarkers of erosive arthritis in systemic lupus erythematosus: Application of machine learning models. PLoS One2018; 13: 0207926.
72.
LiYJiaRLiuY, et al.Antibodies against carbamylated vimentin exist in systemic lupus erythematosus and correlate with disease activity. Lupus2020; 29(3): 239–246.
73.
Richter CohenMSteinerGSmolenJS, et al.Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol1998; 37: 421–424.
74.
BallEMGibsonDSBellAL, et al.Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus2014; 23(1): 46–56.
75.
SuleSDMoodalbailDGBurnhamJ, et al.Predictors of arthritis in pediatric patients with lupus. Pediatr Rheumatol Online J2015; 13: 30.
76.
SchinnerlingKAguillonJCCatalanD, et al.The role of interleukin‐6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol2017; 189: 12–20.
77.
EilertsenGØNikolaisenCBecker-MerokA, et al.Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus. 2011; 20(6):607–613.
78.
PelletierMMaggiLMichelettiAet al.Evidence for a cross-talk between human neutrophils and Th17 cells. Blood2010; 115: 335–343.
79.
ZickertAAmoudruzPSundstromY, et al.IL-17 and IL-23 in lupus nephritis – association to histopathology and response to treatment. BMC Immunol2015; 16: 7.
80.
LongLLiuYWangS, et al.Dickkopf-1 as potential biomarker to evaluate bone erosion in systemic lupus erythematosus. J Clin Immunol2010; 30: 669–675.
81.
RossiniMViapianaOAdamiS, et al.In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density. Clin Exp Rheumatol2015; 33(1): 77–83.
82.
XueJYangJYangL, et al.Dickkopf-1 is a biomarker for systemic lupus erythematosus and active lupus nephritis. J Immunol Res2017; 2017: 6861575.
83.
PigaMCongiaMBalestrieriA, et al.Imbalanced MMP-3 and MMP-12 serum levels in systemic lupus erythematosus patients with Jaccoud's arthropathy and a distinctive MRI pattern. Rheumatol2021; 60(9): 4218–4228.
84.
KlareskogLRönnelidJSaevarsdottirS, et al.The importance of differences; On environment and its interactions with genes and immunity in the causation of rheumatoid arthritis. J Intern Med2020; 287: 514–533.
85.
SalemmeRPeraltaLNMekaSH, et al.The role of NETosis in systemic lupus erythematosus. J Cell Immunol2019; 1: 33–42.
86.
VillanuevaEYalavarthiSBerthierCC, et al.Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol2011; 187: 538–552.
87.
WangZNichollsSJRodriguezER, et al.Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med2007; 13: 1176–1184.
88.
NakaboSHashimotoMItoS, et al.Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies. Rheumatology (Oxford)2017; 56: 1217–1226.
89.
NakaboSOhmuraKAkizukiS, et al.Activated neutrophil carbamylated albumin via the release of myeloperoxidase and reactive oxygen species regardless of NETosis. Mod Rheumatol2020; 30: 345–349.
90.
CatrinaAISvenssonCIMalmströmV, et al.Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. Nat Rev Rheumatol2017; 13: 79–86.
91.
HubbardELCatalinaMDHeuerS, et al.Analysis of gene expression from systemic lupus erythematosus synovium reveals myeloid cell-driven pathogenesis of lupus arthritis. Sci Rep2020; 10: 17361.
92.
ManziSSanchez-GuerreroJMerrillJT, et al.Effects of belimumab, a B lymphocyte stimulator- specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis2012; 71: 1833–1838.
93.
IaccarinoLAndreoliLBocciEB, et al.Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun2018; 86: 1–8
94.
IaccarinoLBettioSReggiaR, et al.Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res2017; 69(1): 115–123.
95.
CeccarelliFCiprianoENatalucciF, et al.Belimumab is able to induce a significant improvement of joint activity status in patients diagnosed with systemic lupus erythematosus: results from a 12-month longitudinal study. Isr Med Assoc J2020; 22(7): 415–419.
96.
OhataJZvaiflerNJNishioM, et al.Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol2005; 174: 864–870.
97.
TanSMXuDRoschkeV, et al.Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum2003; 48: 982–992.
98.
IkedaKSanayamaYMakitaS, et al.Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol2013; 2013: 697525.
99.
PigaMGabbaACauliA, et al.Rituximab treatment for 'rhupus syndrome': clinical and power-Doppler ultrasonographic monitoring of response. A longitudinal pilot study. Lupus2013; 22: 624–628.
100.
GarufiCMancusoSSpinelliFR, et al.Janus kinases inhibitors for treating patients with rhupus. Joint Bone Spine2020; 87: 673–674.
101.
OlivieriGCeccarelliFNatalucciF, et al.Five-years drug survival of mycophenolate mofetil therapy in patients with systemic lupus erythematosus: comparison between renal and non-renal involvement. Joint Bone Spine2021; 88: 105246.
